Liranafate (6-methoxy-2-N-methyl-aminopyridine-thiocarboxylic acid-(5,6,7,8 tetrahydro)-β-Naphthyl ester), a new antifungal drug, is synthesis inhibitor of squalene epoxidase inhibitor and cytoderm inhibitor, which was manufactured by Tosoh Corporation and Zenyaku Kogyo Corporation. It firstly came to the market in August 2000 in Japan. By inhibiting the squalene epoxide reactions of fungal cells and detering the synthesis of ergosterol, which is a constituent of cell membrane. The antifungal activity of Liranafate is 8 times as high as that of Tolnaftate. Liranafate is especially effective against trichophyton rubrum.

Terofenamate (or etoclofene), the ethoxy methyl ester of N-(2,6-dichloro-m-tolyl)anthranilic acid, is a non-steroid anti-inflammatory agent. The drug showed a low level of toxicity and was well tolerated in animals.

Tetroxoprim is an inhibitor of bacterial dihydrofolate reductase. In combination with sulfadiazine (co-tetroxazine) it has been used for the treatment of susceptible bacterial infections.

Lonazolac is a nonsteroidal anti-inflammatory drug. The mononuclear cell response to a synovial stimulus can be abolished by very low concentrations of lonazolac. This blockade can be completely released by the addition of prostaglandin E2. Lonazolac appears therefore as an agent able in addition to modulate the immune response. The release of histamine from human basophils was significantly decreased after preincubation of the cells with lonazolac Ca. Preincubation of human polymorphonuclear leukocytes with lonazolac Ca led to an inhibition of leukotriene generation induced by either the Ca ionophore or opsonized zymosan. Lonazolac Ca affected different enzymes of the platelet activating factor metabolism. After pre- and post-treatment with lonazolac-Ca, the numbers of animals with lung metastases and the score of metastases significantly decreased. Lonazolac-Ca is indicated for the treatment of painful inflammatory rheumatic diseases of the joints and the spine. Acute irritation in osteoarthritis and spondylosis. Soft tissue rheumatism. Post-traumatic and postoperative pain and swelling states.

Fentiazac is a non-steroidal anti-inflammatory agent developed for the treatment of pain disorders. The drug was marketed under the name Norvedan, however, its current marketing status is unknown and supposed to be "discontinued".

Tralonide, a new topical steroid, can be used in atopic dermatitis.

Alfacalcidol (1-hydroxyvitamin D3) is a synthetic analog of vitamin D introduced clinically in the early 1970s. A prodrug for calcitriol (1,25-dihydroxyvitamin D3), it is one of the most potent and rapidly acting compounds currently used in the prevention and treatment of vitamin D deficiency states and hypocalcemia. The clinical benefit of alfacalcidol is related to the stimulation of calcium and phosphorus absorption, reversal of myopathy, promotion of mineralization in bone and the ability to reabsorb fully mineralized bone. Similar marketed vitamin D compounds include calcitriol and ergocalciferol. Alfacalcidol is indicated in conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function.

Razoxane (ICRF 159; (±)1,2-di(3,5-dioxopiperazin-1-yl) propane) belongs to the family of bis-dioxopiperazines, developed in the 1960s as derivatives of the chelating agent EDTA. It exerts antineoplastic, antiangiogenic, and antimetastatic activities. It is an inhibitor of topoisomerase II. Razoxane is a cytostatic agent, blocks the entry of cultured human lymphocytes into mitosis and arrests dividing cells in prophase and early metaphase. Razoxane is an effective drug in the systemic treatment of psoriasis.

Tilmacoxib [JTE 522] is an orally active, potent and highly selective cyclo-oxygenase-2 (COX-2) inhibitor. It entered phase II clinical trials for the treatment of Familial adenomatous polyposis, rheumatoid arthritis, osteoarthritis, and acute pain in Japan, but was discontinued in 2003.